On its third quarter of 2026 earnings call, held on Oct. 27, 2026, Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced that it raised its full-year 2026 revenue guidance to between $1.045 billion and $1.050 billion. Generating profitable sales growth from its flagship drug helps to fund pipeline advancement. Three takeaways from the call stand out for long-term investors. Sales of ARCALYST, the company's approved treatment for recurrent pericarditis, an inflammatory heart condition, drove a guidance increase as more physicians prescribed the therapy earlier in disease progression. Expanding adoption into broader patient populations creates a durable revenue base that supports self-funded growth.
CryptoAlerta — análise de criptomoedas e mercado em tempo real